Qsam Biosciences Inc (QSAM)
$8.30
$-30,999,991.70
(-100.00%)
As on 02-May-2024 15:59EDT
Market cap
$37 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
201.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-2 Mln
-
ROE
-33.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-8
-
Debt to Equity
0
-
Book Value
$0.2
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
2,222
10 Years Aggregate
CFO
$-13.69 Mln
EBITDA
$-35.59 Mln
Net Profit
$-42.87 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Qsam Biosciences Inc (QSAM)
| -100.0 | -100.0 | -100.0 | -100.0 | -98.3 | -83.1 | -69.5 |
|
BSE Sensex*
| -11.7 | -2.7 | -8.0 | -8.0 | 6.2 | 7.8 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Qsam Biosciences Inc (QSAM)
| 43.5 | -41.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Qsam Biosciences Inc (QSAM)
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license... agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas. As of May 3, 2024, QSAM Biosciences, Inc. operates as a subsidiary of Telix Pharmaceuticals (Us) Inc. Read more
-
Co-Founder & Executive Chairman
Dr. C. Richard Piazza MA, Ph.D.
-
Co-Founder & Executive Chairman
Dr. C. Richard Piazza MA, Ph.D.
-
Headquarters
Austin, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Qsam Biosciences Inc (QSAM)
What is the current share price of Qsam Biosciences Inc (QSAM) Today?
The share price of Qsam Biosciences Inc (QSAM) is $8.30 (NASDAQ) as of 02-May-2024 15:59 EDT. Qsam Biosciences Inc (QSAM) has given a return of -98.28% in the last 3 years.
What is the current PB & PE ratio of Qsam Biosciences Inc (QSAM)?
Since, TTM earnings of Qsam Biosciences Inc (QSAM) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-5.01
|
32.75
|
|
2022
|
-1.41
|
-7.07
|
|
2021
|
-0.01
|
0.51
|
|
2020
|
-1.86
|
-2.33
|
|
2019
|
-0.01
|
-0.01
|
What is the 52 Week High and Low of Qsam Biosciences Inc (QSAM)?
The 52-week high and low of Qsam Biosciences Inc (QSAM) are Rs -- and Rs -- as of 31-May-2026.
What is the market cap of Qsam Biosciences Inc (QSAM)?
Qsam Biosciences Inc (QSAM) has a market capitalisation of $ 37 Mln as on 02-May-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Qsam Biosciences Inc (QSAM)?
Before investing in Qsam Biosciences Inc (QSAM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.